Trade EDIT stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Editas Medicine, Inc. (EDIT) is trading at US$2.73, down 2.15% today as of Oct 6, 16:00 EDT. The company has a market capitalisation of US$477.63M. Over the past 52 weeks, EDIT has traded between US$1.66 and US$4.54. On Syfe you can trade EDIT with $0 commission and add it to your watchlist.
| Previous close | US$2.79 |
|---|---|
| Market cap | US$477.63M |
| 52-week range | US$1.66 – US$4.54 |
| Volume | 2.96M |
| Exchange | US |
Editas Medicine, Inc.
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu on September 3, 2013 and is headquartered in Cambridge, MA.
Year: 2016
Editas Medicine Files $400 Million Mixed Shelf
Aug 31, 9:15 PM · MT Newswires
Ladenburg Thalmann Initiates Editas Medicine at Buy With $6 Price Target
Aug 18, 11:01 AM · MT Newswires
Editas Medicine Prices Public Offering of Shares, Warrants
May 26, 2:44 PM · MT Newswires
Editas Medicine, Inc. (EDIT) stock is trading at US$2.73, -2.15% from the previous close of US$2.79.
The market cap for Editas Medicine, Inc. (EDIT) stock is approximately US$477.63M.
The 52-week high for Editas Medicine, Inc. (EDIT) stock is US$4.54.
The 52-week low for Editas Medicine, Inc. (EDIT) stock is US$1.66.
Editas Medicine, Inc. (EDIT) does not currently pay a dividend.
Stay on top of EDIT
Price moves, news and earnings — straight to your inbox.
Snapshot
Popular Stocks in Singapore
